论文部分内容阅读
目的了解四川省德阳地区宫颈组织中23种人乳头瘤病毒(Human papilloma virus,HPV)感染情况(亚型分布、单一和混合感染构成以及感染女性年龄分布)。方法对2014年1月至2015年1月在德阳市人民医院体检和就诊的3 008例女性的宫颈标本应用多聚酶链反应(polymerase chain reaction,PCR)-反向点杂交法进行HPV分型检测,并对所得数据进行统计分析。结果 3 008例标本中,阳性1 010例,感染率为33.58%;其中单一感染726例(70.88%),单一高危型感染560例(18.62%),单一低危型感染166例(5.52%),单一感染例数是多重感染的2.56倍;多重感染284例(28.11%),以双重感染为主(69.37%);双重感染中以高危型和高危型混合感染为主(61.42%),而三重及以上感染以高危型和低危型混合感染为主(73.56%);41~50岁年龄段的患者感染最多,但≤20岁和>50岁年龄段的患者组检出阳性率最高。结论德阳地区有较高的HPV感染率,且本地区HPV感染亚型和年龄段分布具有独特的区域特点。本研究结果可为本地区宫颈病变的诊断、治疗,宫颈癌的早期预防和HPV疫苗使用等提供重要的参考依据。
Objective To investigate the infection status of 23 human papilloma virus (HPV) in cervical tissues in Deyang area of Sichuan Province (subtype distribution, single and mixed infection and age distribution of infected women). Methods Cervical specimens of 3 008 women who were examined and treated in Deyang People’s Hospital from January 2014 to January 2015 were genotyped by polymerase chain reaction (PCR) - reverse dot blot hybridization. And statistical analysis of the data obtained. Results Among 3 008 specimens, the positive rate was 10 010 with a prevalence of 33.58%. Among them, 726 (70.88%) were single infections, 560 (18.62%) were single high-risk infections, 166 (5.52%) were single low- , And the number of single infections was 2.56 times of that of multiple infections. The number of multiple infections was 284 (28.11%) and mainly of double infections (69.37%). The prevalence of double infection was 61.42% in high-risk and high- Infections with triple or more infections were mainly at high risk and low risk (73.56%). Patients in the 41-50 age group had the highest number of infections, but patients in the age group of ≤20 and> 50 years had the highest positive rate. Conclusion There is a high HPV infection rate in Deyang area, and the distribution of HPV subtypes and age groups in this area has unique regional characteristics. The results of this study may provide an important reference for the diagnosis and treatment of cervical lesions in the region, early prevention of cervical cancer and HPV vaccine use.